Introduction: Over the past couple of years, the cost of drug development has sharply
increased along with the high rate of clinical trial failures. Such increase in expenses is …

Background: Neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic
lateral sclerosis, Parkinson's disease (PD), spinal cerebellar ataxias, and spinal and bulbar …

Cumulative evidence strongly supports that the amyloid and tau hypotheses are not mutually
exclusive, but concomitantly contribute to neurodegeneration in Alzheimer′ s disease (AD) …

Over the last century, the definitions of pharmaceutical drug and drug discovery have
changed considerably. Evolving from an almost exclusively serendipitous approach, drug …

The objective of this study is to recognize the potential traditional Chinese medicinal
compound by virtual screening and docking analysis for the amyloid-beta disaggregation …

Alzheimer's disease (AD) is a growing global health concern that affects 10% of the
population aged above 65 years. A growing body of evidence indicates that multi-targeted …

Drug discovery is an expensive and complicated process. The drug must fulfill some criteria
of being nontoxic, bioavailable, and potent. In the view of evermore stringent demands about …

Objective To discover lead lupane triterpenoid's potential isolated from Pueraria lobata roots
against β-site amyloid precursor protein cleaving enzyme 1 (BACE1), which serve as a rate …

Over the past two decades, polyoxometalates (POM) have received considerable attention
as solid catalysts, due to their unique physicochemical characteristics, since, first, they have …

Hundreds of millions of US dollars are invested in the research and development of a single
drug. Lead compound development is an area ripe for new design strategies. Therapeutic …